Immune checkpoint inhibitors convey survival benefit in elderly patients with stage IV non-small cell lung cancer
COVAX cuts global COVID vaccine supply estimates by a quarter
13 September 2021UK Covid policies may have disproportionally impacted ethnic minorities at the end of life
13 September 2021Immune checkpoint inhibitors convey survival benefit in elderly patients with stage IV non-small cell lung cancer
Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients with non-small cell lung cancer (NSCLC), ICIs have become one of the standard pharmacological therapies, but elderly patients may be denied these therapies in clinical trials.
